This bilateral agreement between the Spanish multinational, providing the technology internally developed and its partner Reyoung with a well-known trustability in manufacturing capabilities, will constitute a strategic cooperation for anti-infective and antibacterial API production. These drugs are crucial to guaranteeing the health of the population. Both companies consider it essential to ensure the supply of this therapeutic line, especially in these times of shortages and increased supply chain uncertainty for the global pharma industry.

SUANFARMA is committed to health and innovation, which is why it develops and produces accessible raw materials in accordance with the highest regulatory requirements of the EMA or the FDA. Moreover, the company is also devoted to environmentally responsible practices, embracing green chemistry and prioritizing environmental protection. To this end, their robust R&D team works on the development of technologies to achieve maximum efficiency in its processes, to incorporate cutting-edge active ingredients into its portfolio.

The innovative technology developed by SUANFARMA involves Flow Chemistry, improving yields, selectivity and reproducibility of the processes. It minimizes reaction times and requires smaller quantities of reagents and solvents, reducing raw material use and environmental impact. In addition, this technique is generally safer than traditional synthesis, reducing the risk of explosions and leaks of hazardous reagents.

"We are thrilled to join forces with SUANFARMA as we embark on this transformative collaboration, which marries innovation with exceptional product delivery. This alliance marks the beginning of an exciting journey, and we are confident that our collaboration will deliver immense value to our customers and partners by harnessing the unique strengths and capabilities of each organization", declares Mr. Xie- Reyoung Pharmaceutical Vice-President

"This important strategic agreement between Reyoung and SUANFARMA highlights our shared commitment to technology-driven innovation and maximizing efficiency in order to provide superior products to the patients. Reyoung's exceptional partnership as our ally strengthens our global position, marking the first milestone in what we anticipate will be an immensely promising collaboration between our organizations", says Javier Calvo, SUANFARMA R&D Director.

This significant agreement is expected to be the beginning of a strong with very promising results for the benefit of the patients.

We are fully committed to enhancing the health of both humans and animals, striving to prevent diseases in a sustainable manner.